11β-hydroxylase deficiency epidemiology and demographics

Jump to navigation Jump to search

Congenital adrenal hyperplasia main page

11β-hydroxylase deficiency Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating 11β-hydroxylase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

11β-hydroxylase deficiency epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 11β-hydroxylase deficiency epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 11β-hydroxylase deficiency epidemiology and demographics

CDC on 11β-hydroxylase deficiency epidemiology and demographics

11β-hydroxylase deficiency epidemiology and demographics in the news

Blogs on 11β-hydroxylase deficiency epidemiology and demographics

Directions to Hospitals Treating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency

Risk calculators and risk factors for 11β-hydroxylase deficiency epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]

Overview

Worldwide, the prevalence of 11β-hydroxylase deficiency is 1 per 100,000 persons. 11β-hydroxylase deficiency accounts for 5 percent of all cases of congenital adrenal hyperplasia and it is considered the second most frequent variant after 21-hydroxylase deficiency. The incidence of 11β-hydroxylase deficiency is 1 per 100,000 persons. Also, this disease is more common in Moroccan Jews living in Israel, occurring in approximately 20 in 100,000 newborns. 11β-hydroxylase deficiency affects males and females equally.

Epidemiology and Demographics

Prevalence

  • Worldwide, the prevalence of 11β-hydroxylase deficiency is 1 per 100,000 persons.

Incidence

  • 11β-hydroxylase deficiency accounts for 5 percent of all cases of congenital adrenal hyperplasia and it is considered the second most frequent variant after 21-hydroxylase deficiency.
  • Worldwide, the incidence of 11β-hydroxylase deficiency is 1 per 100,000 persons.
  • 11β-hydroxylase deficiency is more common in Moroccan Jews living in Israel, occurring in approximately 20 in 100,000 newborns.[1][2]

Gender

  • 11β-hydroxylase deficiency affects males and females equally.

Race

  • 11β-hydroxylase deficiency usually affects individuals of the Jewish race.

References

  1. Rösler A, Leiberman E, Cohen T (1992). "High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco". Am J Med Genet. 42 (6): 827–34. doi:10.1002/ajmg.1320420617. PMID 1554023.
  2. White PC, Curnow KM, Pascoe L (1994). "Disorders of steroid 11 beta-hydroxylase isozymes". Endocr. Rev. 15 (4): 421–38. doi:10.1210/edrv-15-4-421. PMID 7988480.